IFNG and hemophagocytic syndrome: Given the importance of the IFN-γ signaling pathway in IEC-HS, as in other HLH-like conditions, ruxolitinib or emapalumab (used more frequently in pediatrics) are being employed for high grade/progressive IEC-HS (114, 121).